GeneDx prelim Q4 revenue beats expectations
Overview
Genomics leader's preliminary Q4 2025 revenue beats analyst expectations
Exome and genome revenue grew 54% yr/yr for full year 2025
Company issues 2026 guidance with expected revenue of $540 to $555 mln
Outlook
GeneDx expects full-year 2026 revenue between $540 mln and $555 mln
Company anticipates 33-35% growth in exome and genome volume for 2026
GeneDx projects at least 70% adjusted gross margin for full-year 2026
Result Drivers
EXOME AND GENOME GROWTH - Exome and genome revenues increased 54% yr/yr for 2025, driven by volume growth and strategic expansions
VOLUME GROWTH - Exome and genome test result volume grew 30.5% yr/yr, demonstrating strong demand and operational scale
STRATEGIC EXPANSION - Company expanded into general pediatrics and prenatal diagnostics, unlocking new growth opportunities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $121 mln | $116.90 mln (7 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for GeneDx Holdings Corp is $165.00, about 21.9% above its January 9 closing price of $135.38
The stock recently traded at 243 times the next 12-month earnings vs. a P/E of 47 three months ago
Press Release: ID:nBw5YfVpqa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
Related Articles
Netflix After the Warner Deal: What Investors Should Know
TradingKey - For quite some time now, Netflix (NFLX) has been regarded as the premier subscription-based streaming service in the world, with a well-established history of growth through creative use of pricing power, developing hit programming, and relying very little on outside sources for licensi
Warsh’s Fed Era Signals a Death Knell for QE, Jolting the $30 Trillion Treasury Market
With Warsh’s nomination, his past proposals for governing the Federal Reserve are being brought to the forefront. A central issue is the formulation of a new "1951 Accord" to restructure the relationship between the Fed and the Treasury. Analysts suggest such a move could impact the $30 trillion Tre
Amazon Stock Predictions for 2026 to 2030: Will They Exceed Expectations and Achieve Major Long-Term Goals?
TradingKey - As we head into 2026, many investors are questioning where Amazon (AMZN) fits into the technology world.
A Crash After a Surge: Why Silver Lost 40% in a Week?
TradingKey - Spot silver (XAGUSD) prices continue to decline. Silver plunged 20% on Thursday, breaking below $71 per ounce, with the sell-off intensifying on Friday as prices fell further below $64. Compared to the all-time high set on January 29, silver prices have retraced more than 40%, wiping out nearly all gains accumulated over the previous month.
